Dr Bonino and colleagues from Italy conducted a trial of patients with Hepatitis B e antigen-negative chronic Hepatitis B.
The team assessed the patients' 24 week post-treatment biochemical, and virological response rates with peginterferon alpha-2a with or without limousine.
The team found that the response rates were significantly higher with peginterferon alpha-2a than with lamivudine alone.
The research team then investigated the effect of pre-treatment factors on post-treatment responses.
|The response rate was 19% with combination therapy|
The team performed multivariate analyses using available data from 518 patients.
The patients were treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone.
A post-treatment response was defined as alanine aminotransferase normalisation and Hepatitis B virus DNA level of less than 20,000 copies/ml.
The team found that across all treatment arms, peginterferon alpha-2a therapy, and younger age predicted combined response 24 weeks post-treatment.
The research team noted that female gender, and baseline alanine aminotransferase were predictors of combined response.
Low baseline Hepatitis B virus DNA and Hepatitis B virus genotype were identified as significant predictors of combined response at 24 weeks post-treatment.
In the peginterferon alpha-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients.
The team found that genotype D infected patients responded better to the combination than to peginterferon alpha-2a monotherapy.
At 1 year post-treatment, the response rate by intention-to-treat analysis was 19% for the peginterferon alpha-2a.
The researchers observed that the response rate by intention-to-treat analyses was also 19% for the combination group.
The team noted that response rate by intention-to-treat was 10% for the lamivudine groups.
Genotypes B or C were associated with a sustained combined response to peginterferon alpha-2a with or without lamivudine therapy.
Dr Bonino's team concludes, “Alanine aminotransferase and Hepatitis B virus DNA levels, patient age, gender, and infecting Hepatitis B virus genotype significantly influenced combined response at 24 weeks post-treatment.”
“At 1 year post-treatment, Hepatitis B virus genotype was significantly predictive of efficacy for patients treated with peginterferon alpha-2a with or without lamivudine.”